Health Catalyst Inc. (NASDAQ:HCAT) finished Wednesday with a subtraction of -$0.1 to close at $10.04, a downside of -0.99 percent. An average of 1,049,900 shares of common stock have been traded in the last five days. There was a fall of -$1.13 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 1,210,660 shares traded, while the 50-day average volume stands at 1,285,892.
HCAT stock has decreased by -19.81% in the last month. The company shares reached their 1-month lowest point of $9.89 on 09/19/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $9.89 and a high of $54.42 in 52 weeks. It has reached a new high 1 time so far this year and lost -74.66% or -$29.58 in price. In spite of this, the price is down -81.55% from the 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
7 days have passed since Health Catalyst Inc. (HCAT) last reported insider trading activity. Llewelyn Linda, who is Chief People Officer, most recently acquired $648 shares at $10.99 per share on Sep 15. In this transaction, the insider spent $7,122. General Counsel, Orenstein Daniel H., disposed of 2,838 shares at a price of $11.27 on Sep 06. The insider now owns more than $31,978 worth of shares. Prior to that, Chief Accounting Officer Alger Jason went on to Sale 262 shares at $11.28 each on Sep 06. An amount of $2,955 was transacted.
Health Catalyst Inc. (HCAT) has a trailing price-to-sales (P/S) ratio at 2.19, the price-to-book (PB) ratio at 1.15.
The quick ratio of Health Catalyst Inc. for the three months ended March 30 was 5.20, and the current ratio was 5.20, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.48 and a total debt to equity ratio of 0.00 for the quarter ending March 30. Its gross profit as reported stood at $117.57 million compared to revenue of $241.93 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Health Catalyst Inc.’s return on assets was -17.50%.
For the three-month period that ended March 30, Health Catalyst Inc. had $226.37 million in cash and short-term investments compared to $225.77 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$33.43 million in the quarter, while revenues of -$22.46 million were shrunk -7.18%. The analyst consensus anticipated Health Catalyst Inc.’s latest quarter earnings to come in at -$0.11 per share, but it turned out to be -$0.06, a 45.50% surprise. For the quarter, EBITDA amounted to -$20.2 million. Shareholders own equity worth $54.72 million.
From a technical analysis perspective, let’s take a brief look at Health Catalyst Inc. (HCAT) price momentum. RSI 9-day as of the close on 21 September was 28.23%, suggesting the stock is oversold, with historical volatility in this time frame at 54.55%.
As of today, HCAT’s price is $10.34 -10.12% or -$1.13 from its 5-day moving average. HCAT is currently trading -18.64% lower than its 20-day SMA and -43.60% lower than its 100-day SMA. However, the stock’s current price level is -38.06% below the SMA50 and -74.19% below the SMA200.
The stochastic %K and %D were 11.02% and 12.80%, respectively, and the average true range (ATR) was 0.61. With the 14-day stochastic at 7.50% and the average true range at 0.68, the RSI (14) stands at 32.44%. The stock has reached -0.59 on the 9-day MACD Oscillator while the 14-day reading was at -0.80.
KeyBanc Capital Markets launched coverage on Health Catalyst Inc. (NASDAQ: HCAT) in its analyst report released on September 16, 2022. The firm assigned the stock a Sector weight rating. The consensus rating for Health Catalyst Inc. (HCAT) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell HCAT, while 4 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 12 others rate it as a “buy”.
What is HCAT’s price target for the next 12 months?
Analysts predict a range of price targets between $11.00 and $25.00, with a median target of $18.00. Taking a look at these predictions, the average price target given by analysts for Health Catalyst Inc. (HCAT) stock is $17.71.